HIFU continues to represent a promising minimally invasive approach for many men with prostate cancer. What its exact role will become remains unclear.
HIFU uses ultrasound to induce tissue damage by thermal and mechanical effects and cavitation. It requires general or spinal anesthesia, and based on the size of the gland, can be time consuming, with about 10 grams of tissue treated per hour. While generally safe, HIFU is not devoid of side effects, with erectile dysfunction, strictures, urinary retention, incontinence, and urinary tract infections reported.
HIFU is approved and has been available in many European countries and Canada for several years. However, in addition to minimizing potential side effects, there are challenges in interpreting the oncologic outcome in treated patients. As noted by the European Association of Urology (EAU), no international consensus on objective response criteria exists. Some authors have adopted the parameters used for radiation therapy, but this is not universally accepted. In 2011, the EAU classified HIFU as "experimental or investigational." In the U.S., HIFU therapy is only available through a clinical trial.
Defining HIFU's optimum patient characteristics, agreement on the definition of oncologic outcomes, refining its technical aspects, and achieving FDA approval remain considerable challenges. While progress is being made, it remains uncertain if and when HIFU will be available in the U.S. and accepted internationally as a standard of care.
Leonard G. Gomella, MD
Dr. Gomella, a member of the Urology Times Editorial Council, is chairman of the department of urology and associate director of clinical affairs, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.